Engel, Anna L.
Lorenz, Nadja I.
Klann, Kevin
Münch, Christian
Depner, Cornelia
Steinbach, Joachim P.
Ronellenfitsch, Michael W.
Luger, Anna-Luisa
Article History
Received: 2 September 2019
Revised: 7 February 2020
Accepted: 26 February 2020
First Online: 17 March 2020
Change Date: 6 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-021-01517-4
Ethics approval and consent to participate
: The human cell lines used in this study are all commercially or academically available and were not generated in the course of this study, and therefore no ethics approval was necessary for the cell line experiments. LNT-229 and LN-308 cells were a kind gift from N. de Tribolet (Lausanne, Switzerland), G55 cells were a kind gift from Manfred Westphal and Kathrin Lamszus (Hamburg), LN-428 cells and LN-464 cells were a kind gift from Monika Hegi (Lausanne). MDA-MB-231 and MDA-MB-464 cells were a kind gift from Winfried Wels (Frankfurt, Germany). LN-229 cells stably expressing a shRNA targeting <i>HIF-1α, HIF-2 α, HIF-1</i> + <i>2α</i> and control (<i>SIMA, homologue of HIF-1α in drosophila</i>), were kindly provided by C. Depner and T. Acker.
: Not applicable.
: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Supplementary information is available at the British Journal of Cancer’s website.
: J.P.S. reports honoraria for lectures or advisory board participation or consulting or travel grants from Abbvie, Roche, Boehringer, Bristol-Myers Squibb, Medac, Mundipharma and UCB. All other authors declare no conflicts of interest. M.W.R. reports a research grant from UCB.
: The Dr Senckenberg Institute of Neurooncology is supported by the Dr Senckenberg Foundation. A.L.E. has received a scholarship by the Adolf Gutknecht trust. C.M. acknowledges funding from the German Research Foundation (DFG) Emmy Noether Program (MU 4216/1-1) and the Frankfurt Cancer Institute. JPS has received funding by the German Research Foundation (DFG; DFG 2175/1-1). J.P.S. and M.W.R. have received funding by the State of Hessen within the LOEWE program. M.W.R. has received a fellowship by the University Cancer Centre Frankfurt (UCT) as well as funding by the Frankfurt Research Funding (FFF) ‘Clinician Scientists Program’. A.L.L. has received funding by the FFF program “Patenschaftsmodell” and a fellowship in the program “Clinical Scientist” by the Else Kröner research college (EKF). Open Access funding enabled and organized by Projekt DEAL.